Advanced Filters
noise

Madison, Wisconsin Clinical Trials

A listing of Madison, Wisconsin clinical trials actively recruiting patient volunteers.

Found 457 clinical trials
S Sean Prahl

Temporal Interference for Thalamocortical Activity and Network Modulation

The goal of this clinical trial is to find out whether a type of electrical brain stimulation, called temporal interference stimulation, can temporarily change the way different parts of the brain communicate with each other. Participants will: Complete two stimulation phases - overnight and during wakefulness Undergo two MRIs per …

18 - 50 years of age All Phase 1
L Lucas Modahl

Hearing Aid Benefit in Real-World Noisy Environments

Researchers are doing this study to understand why hearing aids often work well in controlled laboratory settings but don't provide the same level of benefit in everyday noisy environments. The questions they hope to answer are: What factors contribute to hearing aid benefit in noisy environments What factors limit hearing …

18 years of age All Phase N/A
S Sean Prahl

Power Nap With TES-TI

The goal of this clinical trial is to find out whether stimulating the brain with electrical current during naps can increase certain kinds of brain activity that happen during sleep and lead to improvements in mental fatigue. Participants will attend 2 study visits, each of which may last up to …

18 - 75 years of age All Phase N/A

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

This is a Phase 1, multicenter, randomized, double-blind, double-dummy, single dose, placebo- and positive-controlled, 4-sequence, 4-treatment, 4-period crossover study.

18 - 55 years of age All Phase 1

A Study of [14C]-LY4064809 in Healthy Participants

The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will …

18 - 55 years of age All Phase 1

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

The purpose of this study is to learn how a certain amount of \[14C\] PF-07320948 is taken up into the bloodstream and removed from the body. This study is seeking participants who are: Male between 18 to 64 years of age Deemed to be healthy This is a 2 Part, …

18 - 64 years of age Male Phase 1
S Sameek Roychowdhury, MD, PhD

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started to other places in …

18 years of age All Phase 2
S Site Public Contact

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works …

18 years of age All Phase 2

Diffusion MRI of the Abdomen

The purpose of this research is to see if a new magnetic resonance imaging (MRI) method will be able to improve the images taken of the abdomen. This new method includes some changes to help avoid movements that may disrupt the images like breathing, heartbeats and other involuntary motion that …

18 years of age All Phase N/A

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

18 years of age All Phase 1

Simplify language using AI